Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuthavong, Yongyuth, Tarnchompoo, Bongkoch, Vilaivan, Tirayut, Chitnumsub, Penchit, Kamchonwongpaisan, Sumalee, Charman, Susan A., McLennan, Danielle N., White, Karen L., Vivas, Livia, Bongard, Emily, Thongphanchang, Chawanee, Taweechai, Supannee, Vanichtanankul, Jarunee, Rattanajak, Roonglawan, Arwon, Uthai, Fantauzzi, Pascal, Yuvaniyama, Jirundon, Charman, William N., Matthews, David
Format: Artigo
Language:Inglês
Published: National Academy of Sciences 2012
Subjects:
Biological Sciences
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3479511/
https://ncbi.nlm.nih.gov/pubmed/23035243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1204556109
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items